Cases Presented With Fluidx GPX Embolic Device to Treat Arterial and Venous Tumor
Created with Sketch.
February 2, 2021—Fluidx Medical Technology announced that the first patient-use cases with the company’s GPX embolic device were presented by Andrew Holden, MD, at LINC 2021, the Leipzig Interventional Course held January 25-29.
According to the company, the GPX embolic device is designed to combine the benefits of other embolics such as coils, particles, and liquids with simplified preparation, delivery, precision, and control leading to durable, long-term occlusions. The GPX technology is a low-viscosity, aqueous-based solution in a syringe that solidifies into a durable embolic material on delivery, without polymerization or dimethyl-sulfoxide precipitation associated with other embolics. The GPX embolic device is not available for sale in the United States or other markets and is for investigational use only, advised the company.